Results 71 to 80 of about 16,645 (269)
Research and Practice in Thrombosis and Haemostasis, 2022 Introduction The activated partial thromboplastin time (aPTT) and the prothrombin time (PT) are widely available coagulation parameters which are however poor predictors of the anticoagulant effect of direct oral anticoagulants (DOACs).
Jonathan Evrard +8 more
doaj +1 more source
New oral anticoagulants and their reversal agents [PDF]
, 2018 Atrial fibrillation is a commonly encountered pathology in medical practice, and its prevalence has shown a continuous rise over the past years. Atrial fibrillation has a significant impact on patients\u27 quality of life, not only due to the standard ...
Bodean, Oana +9 more
core +1 more source
Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms [PDF]
, 2016 A growing body of evidence suggests that atrial fibrillation (AF) is associated with myocardial infarction (MI). However, incidence and management of MI in AF is still undefined. METHODS AND RESULTS: We searched MEDLINE via PubMed and Cochrane database
PASTORI, DANIELE +3 more
core +1 more source
Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions
International Journal of Laboratory Hematology, EarlyView.ABSTRACT Introduction There are important challenges with the measurement and interpretation of direct oral anticoagulant (DOAC) anticoagulant effect including a lack of therapeutic ranges, inaccuracy of routinely available coagulation assays, lack of established thresholds for clinically significant effect, and uncertainty about how to apply the ...
Siraj Mithoowani +2 more
wiley +1 more source
More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. [PDF]
, 2018 © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.Common to the pathogenesis of acute coronary syndromes (ACS) is the formation of arterial thrombus, which results from platelet activation and triggering of the ...
Farag M +6 more
core +3 more sources
Pacing and Clinical Electrophysiology, EarlyView.ABSTRACT Background The benefit of oral anticoagulation (OAC) in patients with new‐onset postoperative atrial fibrillation (POAF) after coronary bypass grafting remains uncertain. The 2023 American Heart Association (AHA) and the American College of Cardiology (ACC) guidelines recommend 60 days of anticoagulation for POAF, whereas management was ...
Daniel S. Cheah +4 more
wiley +1 more source
Pharmacokinetics of anticoagulant edoxaban in overdose in a Japanese patient transported to hospital
Journal of Pharmaceutical Health Care and Sciences, 2020 Background The anticoagulant edoxaban is used clinically at doses of 30–60 mg/day; however, we experienced a patient who had taken an overdose of edoxaban of 750 mg.
Koichiro Adachi +5 more
doaj +1 more source
Dental management of patients taking novel oral anticoagulants (NOAs): dabigatran [PDF]
, 2017 A new group of oral anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban) with clear advantages over classic dicoumarin oral anticoagulants (warfarin and acenocoumarol) has been developed in recent years.
Albaladejo Martínez, Alberto +2 more
core +2 more sources
Pharmacokinetics and pharmacogenetics of edoxaban
Siberian Medical Review, 2020 Edoxaban is a new generation of oral anticoagulant; it is selective, direct and reversible inhibitor of activated blood coagulation factor X (F Xa), serine protease responsible for thrombin formation. Edoxaban is used to prevent stroke in non-valvular atrial fibrillation, to treat deep vein thrombosis and pulmonary embolism.
A.V. Savinova +5 more
openaire +1 more source
Advances in cardiac devices and bioelectronics augmented with artificial intelligence
The Journal of Physiology, EarlyView.Abstract figure legend Interfaces between the human heart, diagnostic bioelectronics, artificial intelligence, and clinical care. From left to right: Human heart and biosensor interface; representative waveforms of common diagnostic bioelectronic sensing modalities.
Charles Stark +3 more
wiley +1 more source